PMID- 36263137
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221021
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Chuan Huang Fang combining reduced glutathione in treating acute kidney injury 
      (grades 1-2) on chronic kidney disease (stages 2-4): A multicenter randomized 
      controlled clinical trial.
PG  - 969107
LID - 10.3389/fphar.2022.969107 [doi]
LID - 969107
AB  - Lack of effective drugs for acute kidney injury (AKI) grades 1-2 is a crucial 
      challenge in clinic. Our previously single-center clinical studies indicated 
      Chuan Huang Fang (CHF) might have nephroprotection in AKI on chronic kidney 
      disease (CKD) (A on C) patients by preventing oxidant damage and inhibiting 
      inflammation. Reduced glutathione (RG) has recently been shown to increase the 
      clinical effectiveness of high-flux hemodialysis among patients with severe AKI. 
      In this multicenter randomized controlled clinical study, we designed a new 
      protocol to assess the efficacy and safety of CHF combining RG in patients with A 
      on C. We also explored therapeutic mechanisms from renal fibrosis biomarkers. 98 
      participants were randomly and equally divided into the RG and RG + CHF 
      subgroups. The RG and RG + CHF groups received general treatments with RG and a 
      combination of RG and CHF, respectively. The therapy lasted for 2 weeks. In this 
      study, the primary assessment result was a difference in the slope of serum 
      creatinine (Scr) over the course of 2 weeks. The secondary evaluation outcomes 
      were alterations in blood urea nitrogen (BUN), uric acid (UA), estimated 
      glomerular filtration rate (eGFR), urinary AKI biomarkers, renal fibrosis 
      biomarkers (transforming growth factor-beta (1) (TGF-beta (1)), connective tissue 
      growth factor (CTGF)), and traditional Chinese medicine (TCM) symptoms. 
      Furthermore, vital signs and adverse events (AEs) were observed. Both groups had 
      a slower renal function decline after treatment than before treatment. Compared 
      with RG group, more reductions of Scr, BUN, UA, and better improvement of eGFR 
      were observed in RG + CHF group (p < 0.05). Additionally, the levels of urinary 
      AKI biomarkers, renal fibrosis biomarkers, and TCM syndromes were decreased in RG 
      + CHF group versus RG group (p < 0.05). No significant between-group differences 
      were observed of AEs. We thus concluded this novel therapy of CHF combining RG 
      might be a useful method for treating A on C patients.
CI  - Copyright (c) 2022 Chen, Ye, Wang, Liu, Wang, Wang, Xu and Gong.
FAU - Chen, Ling
AU  - Chen L
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Ye, Zi
AU  - Ye Z
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Wang, Danjun
AU  - Wang D
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Liu, Jianlian
AU  - Liu J
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
FAU - Wang, Chen
AU  - Wang C
AD  - Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Xu, Bing
AU  - Xu B
AD  - Department of Nephrology, Minhang Branch of Yueyang Hospital of Integrative 
      Chinese and Western Medicine Affiliated to Shanghai University of Traditional 
      Chinese Medicine, Shanghai, China.
FAU - Gong, Xuezhong
AU  - Gong X
AD  - Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese 
      Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20221003
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9573953
OTO - NOTNLM
OT  - acute kidney injury
OT  - chronic kidney disease
OT  - chuan huang fang
OT  - reduced glutathione
OT  - renal fibrosis
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/21 06:00
MHDA- 2022/10/21 06:01
PMCR- 2022/10/03
CRDT- 2022/10/20 02:56
PHST- 2022/06/14 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/10/20 02:56 [entrez]
PHST- 2022/10/21 06:00 [pubmed]
PHST- 2022/10/21 06:01 [medline]
PHST- 2022/10/03 00:00 [pmc-release]
AID - 969107 [pii]
AID - 10.3389/fphar.2022.969107 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Oct 3;13:969107. doi: 10.3389/fphar.2022.969107. 
      eCollection 2022.